Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic

CPM Duong; CSM Yong; MH Kershaw; CY Slaney; PK Darcy

Journal article

Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic

CPM Duong, CSM Yong, MH Kershaw, CY Slaney, PK Darcy

Molecular Immunology | Published : 2015

DOI: 10.1016/j.molimm.2014.12.009

Abstract

The immune system plays a critical role in the elimination and suppression of pathogens. Although the endogenous immune system is capable of immune surveillance resulting in the elimination of cancer cells, tumor cells have developed a variety of mechanisms to escape immune recognition often resulting in tumor outgrowth. The presence of immune infiltrate in tumors has been correlated with a good prognosis following treatment (. Sato et al., 2005; Loi et al., 2013; Clemente et al., 1996; Galon et al., 2006). As such, immune cells such as T cells, have been harnessed in order to target cancer. Tumor reactive lymphocytes, called tumor-infiltrating lymphocytes (TILs) have been isolated and expan..

View full abstract

University of Melbourne Researchers

Clare Slaney Author

Phillip Darcy Author

Related Projects (4)

UTILIZATION OF GENE-ENGINEERED T CELLS FOR ENHANCING CANCER IMMUNOTHERAPY

Killer T lymphocytes can penetrate tumours and their transfer into cancer patients has demonstrated some encouraging results, but this form ..

Investigating the limits of adoptive immunotherapy

White blood cells from cancer patients can be modified in the laboratory to react against tumours. Although these cells can induce cancer re..

IMMUNE REGULATION EFFECTOR FUNCTION AND THERAPY

We seek to understand how white blood cells detect and destroy disease, and how molecules of the immune system punch holes in diseased cells..

BLOCKING BREAST CANCER CELL TYPE I IFN SIGNALLING PREVENTS IMMUNE RECOGNITION AND ALLOWS METASTATIC PROGRESSION TO BONE

Grants

Awarded by National Health and Medical Research Council

Funding Acknowledgements

This work was funded by Program and Project grants from the National Health and Medical Research Council (NHMRC) (#1013667, #1030436). C. Y. Slaney was supported by a National Breast Cancer Fellowship (#PF-12-14). P. K. Darcy and M. H. Kershaw were supported by NHMRC Senior Research Fellowships (#1041828 and 1058388 respectively).